Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: High yield and preserved bioactivity

Biotechnology and Bioengineering

Volumn 100, Issue 2, 2008, Pages 273-283

  Havenga, M J E ^a   Holterman, L ^a   Melis, I ^a   Smits, S ^a   Kaspers, J ^a   Heemskerk, E ^a   Van Der Vlugt, R ^a   Koldijk, M ^a   Schouten, G J ^a   Hateboer, G ^a   Brouwer, K ^a   Vogels, R ^a   Goudsmit, J ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Human PER.C6 cells; Protein production; Recombinant adenovirus; Serum free medium

Indexed keywords

BIOACTIVITY; BIOASSAY; CELL GROWTH; GENE ENCODING; SIGNAL TRANSDUCTION; VIRUSES;

HUMAN CELLS; PROTEIN PRODUCTION; RECOMBINANT ADENOVIRUS; SERUM-FREE MEDIUM;

PROTEINS;

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; PROTEIN; RECOMBINANT PROTEIN; VIRUS RECEPTOR;

ARTICLE; BIOLOGICAL ACTIVITY; CELL DENSITY; CELL LINE; CORONAVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE TARGETING; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SEVERE ACUTE RESPIRATORY SYNDROME;

ADENOVIRIDAE; BIOTECHNOLOGY; CELL LINE; CULTURE MEDIA, SERUM-FREE; GENETIC ENHANCEMENT; GENETIC VECTORS; HUMANS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; RETINA; TRANSFECTION;

ADENOVIRIDAE; CORONAVIRUS; SARS CORONAVIRUS;

EID: 44449100253     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21757     Document Type: Article

References (62)

1. Andersen DC, Krummen L. 2002. Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol 13(2):117-123.
2. Andersson C, Hansson M, Power U, Nygren Pk, Ståhl S. 2001. Mammalian cell production of a respiratory syncytial virus (RSV) candidate vaccine recovered using a product-specific affinity column. Biotechnol Appl Biochem 34(Pt 1):25-32.
3. Baldi L, Hacker DL, Adam M, Wurm FM. 2007. Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol Lett 29(5):677-684.
4. Bao WG, Fukuhara H. 2001. Secretion of human proteins from yeast: Stimulation by duplication of polyubiquitin and protein disulfide isomerase genes in Kluyveromyces lactis. Gene 272(1-2):103-110.
5. Berg H, Walter M, Mauch L, Seissler J, Northemann W. 1993. Recombinant human preproinsulin. Expression, purification and reaction with insulin autoantibodies in sera from patients with insulin-dependent diabetes mellitus. J Immunol Methods 164(2):221-231.
6. Boedeker BG. 2001. Production processes of licensed recombinant factor VIII preparations. Semin Thromb Hemost 27(4):385-394.
7. Breitbach K, Jarvis DL. 2001. Improved glycosylation of a foreign protein by Tn-5B 1-4cells engineered to express mammalian glycosyltransferases. Biotechnol Bioeng 74(3):230-239.
8. Brink EN van den, Meulen J ter, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, Martina BE, Osterhaus ADME, Preiser W, Doerr HW, Kruif J de, Goudsmit J. 2005. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocaspid proteins of severe acute respiratory syndrome Coronavirus. J Virol 79(3):1635-1644.
9. Cai X. 2001. Melanin properties studies of the recombinant of Pseudomonas pseudoalcaligenes containing tyrosinase gene. Wei Sheng Wu Xue Bao 41(6):699-703.
10. Chen L, Colman PM, Cosgrove LJ, Lawrence MC, Lawrence LJ, Tulloch PA, Gorman JJ. 2001. Cloning, expression, and crystallization of the fusion protein of Newcastle disease virus. Virology 290(2):290-299.
11. Côté J, Garnier A, Massie B, Kamen A. 1998. Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol Bioeng 59(5):567-575.
12. Derouazi M, Girard P, Van Tilborgh F, Iglesias K, Muller N, Bertschinger M, Wurm FM. 2004. Serum-free large-scale transient transfection of CHO cells. Biotechnol Bioeng 87(4):537-545.
13. Ensinger MJ, Ginsberg HS. 1972. Selection and preliminary characterization of temperature-sensitive mutants of type 5 adenovirus. J Virol 10(3):328-329.
14. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, Hoeben RC, Van Der Eb AJ. 1996. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 7(2):215-222.
15. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC. 1998. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9(13):1909-1917.
16. Fang B, Wang H, Gordon G, Bellinger DA, Read MS, Brinkhous KM, Woo SL, Eisensmith RC. 1996. Lack of persistence of El-Recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther 3(3):217-222.
17. Friehs K, Reardon KF. 1993. Parameters influencing the productivity of recombinant E. coli cultivations. Adv Biochem Eng Biotechnol 48:53-77.
18. Fussenegger M, Bailey JE, Hauser H, Mueller PP. 1999. Genetic optimization of recombinant glycoprotein production by mammalian cells. Trends Biotechnol 17(1):35-42.
19. Garnier A, Côté J, Nadeau I, Kamen A, Massie B. 1994. Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology 15(1-3):145-155.
20. Goldman MJ, Litzky LA, Engelhardt JF, Wilson JM. 1995. Transfer of the CFTR gene to the lung of nonhuman primates with El-deleted, E2a-defective recombinant adenoviruses: A preclinical toxicology study. Hum Gene Ther 6(7):839-851.
21. Gorziglia MI, Lapcevich C, Roy S, Kang Q, Kadan M, Wu V, Pechan P, Kaleko M. 1999. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3. J Virol 73(7):6048-6055.
22. Gossen M, Bonin AL, Freundlich S, Bujard H. 1994. Inducible gene expression systems for higher eukaryotic cells. Curr Opin Biotechnol 5(5):516-520.
23. Havenga MJ, Lemckert AA, Grimbergen JM, Vogels R, Huisman LG, Valerio D, Bout A, Quax PH. 2001. Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 75(7):3335-3342.
24. Imler JL, Bout A, Dreyer D, Dieterlé A, Schultz H, Valerio D, Mehtali M, Pavirani A. 1995. Trans-complementation of E1-deleted adenovirus: A new vector to reduce the possibility of co dissemination of wild-type and recombinant adenoviruses. Hum Gene Ther 6(6):711-721.
25. Jackson RJ, Howell MT, Kaminski A. 1990. The novel mechanism of initiation of picornavirus RNA translation. Trends Biochem Sci 15(12):477-483.
26. James E, Lee JM. 2001. The production of foreign proteins from genetically modified plant cells. Adv Biochem Eng Biotechnol 72:127-156.
27. Jenkins N, Buckberry L, Marc A, Monaco L. 1998. Genetic engineering of alpha 2,6-sialyltransferase in recombinant CHO cells. Biochem Soc Trans 26(2):S115.
28. Jønson L, Johnsen AH. 2001. Post-translational modifications of heterologously expressed cholecystokinin in Saccharomyces cerevisiae. Scand J Clin Lab Invest Suppl 234:87-92.
29. Kawashima Y, Ogawa T, Kato M, Nakazato A, Tsuchida K, Hatayama K, Hirono S, Moriguchi I. 1993. Structure-activity study of antihypertensive 1,4-dihydropyridine derivatives having nitrooxyalkyl moieties at the 3 and 5 positions. Chem Pharm Bull (Tokyo) 41(6):1060-1065.
30. Klessig DF, Brough DE, Cleghon V. 1984. Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell. Mol Cell Biol 4(7):1354-1362.
31. Konishi J, Ishii Y, Onaka T, Maruhashi K. 2002. Purification and characterization of the monooxygenase catalyzing sulfur-atom specific oxidation of dibenzothiophene and benzothiophene from the thermophilic bacterium Paenibacillus sp. strain A11-2. Appl Microbiol Biotechnol 60(1-2):128-133. Epub 2002 August 24.
32. Kruijer W, Schaik FM van, Sussenbach JS. 1981. Structure and organization of the gene coding for the DNA binding protein of adenovirus type 5. Nucleic Acid Res 9(18):4439-4457.
33. Ladisch S, Lovejoy FH, Hierholzer JC, Oxman MN, Strieder D, Vawter GF, Finer N, Moore M. 1979. Extrapulmonary manifestations of adenovirus type 7 pneumonia simulating Reye syndrome and the possible role of an adenovirus toxin. J Pediatr 95(3):348-355.
34. Lamarche N, Massie B, Richer M, Paradis H, Langelier Y. 1990. High level expression in 293 cells of the herpes simplex virus type 2 ribonucleotide reductase subunit 2 using an adenovirus vector. J Gen Virol 71(Pt 8):1785-1792.
35. Lawrence SM, Huddleston KA, Tomiya N, Nguyen N, Lee YC, Vann WF, Coleman TA, Betenbaugh MJ. 2001. Cloning and expression of human sialic acid pathway genes to generate CMP-sialic acids in insect cells. Glycoconj J 18(3):205-213.
36. Lazaris A, Arcidiacono S, Huang Y, Zhou JF, Duguay F, Chretien N, Welsh EA, Soares JW, Karatzas CN. 2002. Spider silk fibers spun from soluble recombinant silk produced in mammalian cells. Science 295(5554):472-476.
37. Lee FS, Vallee BL. 1989. Expression of human placental ribonuclease inhibitor in Escherichia coli. Biochem Biophys Res Commun 160(1):115-120.
38. Levy R, Weiss R, Chen G, Iverson BL, Georgiou G. 2001. Production of correctly folded Fab antibody fragment in the cytoplasm of Escherichia coli trxB gor mutants via the coexpression of molecular chaperones. Protein Expr Purif 23(2):338-347.
39. Lochmüller H, Jani A, Huard J, Prescott S, Simoneau M, Massie B, Karpati G, Acsadi G. 1994. Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1 + delta E3) during multiple passages in 293 cells. Hum Gene Ther 5(12):1485-1491.
40. Lusky M, Christ M, Rittner K, Dieterle A, Dreyer D, Mourot B, Schultz H, Stoeckel F, Pavirani A, Mehtali M. 1998. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 72(3):2022-2032.
41. Maizel JV, White DO, Scharff MD. 1968. The polypeptides of adenovirus. I Evidence for multiple protein components in viron and a comparison of types 2,7A and 12. Virology 36:115-125.
42. Marchal I, Jarvis DL, Cacan R, Verbert A. 2001. Glycoproteins from insect cells: Sialylated or not? Biol Chem 382(2):151-159.
43. Massaer M, Mazzu P, Haumont M, Magi M, Daminet V, Bollen A, Jacquet A. 2001. High-level expression in mammalian cells of recombinant house dust mite allergen ProDer p 1 with optimized codon usage. Int Arch Allergy Immunol 125(1):32-43.
44. Massie B, Dionne J, Lamarche N, Fleurent J, Langelier Y. 1995. Improved adenovirus vector provides herpes simplex virus ribonucleotide reductase R1 and R2 subunits very efficiently. Biotechnology (NY) 13(6):602-608.
45. Massie B, Couture F, Lamoureux L, Mosser DD, Guilbault C, Jolicoeur P, Bélanger F, Langelier Y. 1998. Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J Virol 72(3):2289-2296.
46. Mattes R. 2001. The production of improved tissue-type plasminogen activator in Escherichia coli. Semin Thromb Hemost 27(4):325-336.
47. McQuillan DJ, Seo NS, Hocking AM, McQuillan CI. 2001. Recombinant expression of proteoglycans in mammalian cells. Utility and advantages of the vaccinia virus/T7 bacteriophage hybrid expression system. Methods Mol Biol 171:201-219.
48. Menassa R, Zhu H, Karatzas CN, Lazaris A, Richman A, Brandle J. 2004. Spider dragline silk proteins in transgenic tobacco leaves: Accumulation and field production. Plant Biotechnol J 2(5):431-438.
49. Meulen J ter, Bakker AB, Brink EN van den, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, Kruif J de, Preiser W, Spaan W, Gelderblom HR, Goudsmit J, Osterhaus AD. 2004. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363 (9427):2139-2141.
50. Mosser DD, Massie B. 1994. Genetically engineering mammalian cell lines for increased viability and productivity. Biotechnol Adv 12(2): 253-277.
51. O'Neal WK, Zhou H, Morral N, Aguilar-Cordova E, Pestaner J, Langston C, Mull B, Wang Y, Beaudet AL, Lee B. 1998. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha 1-antitrypsin after systemic delivery. Hum Gene Ther 9(11):1587-1598.
52. Reich NC, Sarnow P, Duprey E, Levine AJ. 1983. Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. Virology 128(2):480-484.
53. Rice SA, Klessig DF. 1985. Isolation and analysis of adenovirus type 5 mutants containing deletions in the gene encoding the DNA-binding protein. J Virol 56(3):767-778.
54. Sarkar SN, Sen GC. 1998. Production, purification, and characterization of recombinant 2′,5′-oligoadenylate synthetases. Methods 15(3):233-242.
55. Sarkar S, Miwa N, Kominami H, Igarashi N, Hayashi S, Okada T, Jahangeer S, Nakamura S. 2001. Regulation of mammalian phospholipase D2:Interaction with and stimulation by G(M2) activator. Biochem J 359(Pt 3):599-604.
56. Seo NS, Hollister JR, Jarvis DL. 2001. Mammalian glycosyltransferase expression allows sialoglycoprotein production by baculovirus-infected insect cells. Protein Expr Purif 22(2):234-241.
57. Tait AS, Brown CJ, Galbraith DJ, Hines MJ, Hoare M, Birch JR, James DC. 2004. Transient production of recombinant proteins by Chinese hamster ovary cells using polyethyleneimine/DNA complexes in combination with microtubule disrupting anti-mitotic agents. Biotechnol Bioeng 88(6):707-721.
58. Tom RL, Caron AW, Massie B, Kamen AA. 1995. Scale-up of recombinant virus and protein production in stirred-tank reactors. Methods Mol Biol 39:203-224.
59. Vliet P van der, Levine AJ, Ensinger MJ, Ginsberg HS. 1975. Thermolabile DNA Binding proteins from cells infected with a temperature-sensitive mutant of adenovirus defective in viral DNA synthesis. J Virol 15(2):348-354.
60. Vliet P van der, Sussenbach JS. 1975. An Adenovirus type 5 gene function required for initiation of viral DNA replication. J Virol 67(2):415-426.
61. Wu L, Berk AJ. 1996. Modification of adenovirus as gene transfer vector. Journal of Investigative Medicine 44(1):A190.
62. Zhang WW, Koch PE, Roth JA. 1995. Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. Biotechniques 18(3):444-447.